<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021267</url>
  </required_header>
  <id_info>
    <org_study_id>920136</org_study_id>
    <nct_id>NCT01021267</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions</brief_title>
  <official_title>Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioforce AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bioforce AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment in an open trial if a standardized saw palmetto preparation has a positive
      influence on sexual dysfunctions in patients with BPH and sexual dysfunctions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the brief Sexual Function Inventory</measure>
    <time_frame>day 0 and day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in IPSS change in Urolife Quality of Life questionnaire</measure>
    <time_frame>day 0 and day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sexual Dysfunctions in Men With Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Saw palmetto berry extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saw palmetto berry extract</intervention_name>
    <description>1x daily 1 capsule containing 320mg lipophilic extract</description>
    <arm_group_label>Saw palmetto berry extract</arm_group_label>
    <other_name>Prostasan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with BPH and sexual dysfunctions (erectile dysfunction or decrease in libido)

          -  IPSS &gt; 4

          -  BSFI, sexual drive questions &lt; 5

        Exclusion Criteria:

          -  Lack of libido which is due to a psychic disease or a depressive mood -Excessivly
             strong lack of libido in the judgement of the investigator within the last two months

          -  Patients with severe vascular disorders (microangiopathies)

          -  Patients with known neuropathies

          -  Severe diabetes mellitus

          -  Patients with hypertension who are for less than two months on a stable
             antihypertensive medication

          -  Known bad compliance of the patient
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugen Riedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>independent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andy Suter, M.Sc.</last_name>
    <phone>0041714546203</phone>
    <email>a.suter@bioforce.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Eugen Riedi</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <last_update_submitted>November 25, 2009</last_update_submitted>
  <last_update_submitted_qc>November 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Andy Suter, Head of Med. Dept.</name_title>
    <organization>Bioforce AG</organization>
  </responsible_party>
  <keyword>sexual dysfunctions</keyword>
  <keyword>benign prostatic hyperplasia</keyword>
  <keyword>saw palmetto</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saw palmetto extract</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 22, 2011</submitted>
    <returned>December 22, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

